Not Yet RecruitingNot Applicable

Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate Vaccine

450 participantsStarted 2026-03

Plain-language summary

This study will measure immune persistence of the NmCV-5 more than 5 years after a single dose vaccination in participants 2-29 years of age in Mali and The Gambia.

Who can participate

Age range7 Years – 36 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Written informed consent and assent (if applicable) Exclusion Criteria: * Current or previous, confirmed disease caused by Neisseria meningitidis at any given time since meningococcal vaccination * Any condition or criteria that in the opinion of the investigator might compromise the well-being of the participant or the compliance with study procedures or interfere with the outcome of the study

What they're measuring

Geometric mean titers (GMTs) measured by rSBA against serogroups A, C, Y, W and X

Timeframe: five-six years after vaccination.

Trial details

NCT IDNCT07379151

SponsorSerum Institute of India Pvt. Ltd.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-12

View on ClinicalTrials.gov More Meningoccocal Disease trials